Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Caroverine→

Caroverine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
23465-76-1
Molecular formula
C22H27N3O2
Molecular weight
365.5 g/mol
Drug class
Smooth-muscle spasmolyticcalcium-channel and phosphodiesterase inhibitor properties
Mechanism of action
Relaxes smooth muscle through calcium-channel blocking and phosphodiesterase-inhibitory effects. Proposed additional effects on glutamatergic signalling have been described, but the clinical mechanism is not fully established.
Indications / reported uses
  • Used in some countries for symptomatic relief of visceral smooth-muscle spasm and selected otological or vestibular complaints; indications and evidence vary by jurisdiction and product

Sources: NLM MeSH — Caroverine · PubMed — Caroverine pharmacology and clinical use · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Caroverine Environmental Risk Assessment (ERA) (the Caroverine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.